Evaluation of the impact of egfr decline on clinical practice patterns of medication withdrawal in heart failure

Active Grant Awarded

Award ID
R03DK145928
Recipient
Awarding agency
Obligated
$133,875

Award facts

Completion date 12% complete
Place of performance
Boston, MA 02111, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases awarded Grant R03DK145928 to Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) on Aug 26, 2026, obligating $133,875.00 under Assistance Listing 93.847, Diabetes, Digestive, and Kidney Diseases Extramural Research. The project, "Evaluation of the Impact of EGFR Decline on Clinical Practice Patterns of Medication Withdrawal in Heart Failure," studies whether discontinuing or reducing guideline-directed medical therapy after estimated glomerular filtration rate decline harms patients with heart failure with reduced ejection fraction. The therapy classes under study are renin-angiotensin-aldosterone system inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose co-transporter 2 inhibitors, each of which produces an acute eGFR decline that many clinicians cite as an obstacle to initiating and continuing treatment. The program funds extramural basic and clinical biomedical research aimed at the mechanisms of, and improved prevention, diagnosis, and treatment of, diabetes, digestive, and kidney diseases. The period of performance runs from the award date through Jun 30, 2028, and work is performed in Boston, MA 02111.

Description

Abstract
Heart failure (HF) is a condition that carries very high rates of mortality and morbidity. Guideline-directed medical therapy (GDMT) including renin-angiotensin-aldosterone system inhibitors (RAASI), mineralocorticoid receptor antagonists (MRA), and sodium-glucose CO-transporter 2 inhibitors (SGLT2I) have each been shown to reduce mortality and risk of adverse cardiovascular events, particularly for patients with heart failure with reduced ejection fraction (HFREF). However, each of these GDMT medication classes is also associated with an acute decline in estimated glomerular filtration rate (EGFR) which is considered hemodynamic and benign in nature. For clinicians, however, the EGFR decline following initiation of GDMT appears no different from EGFR decline due to true kidney injury, creating a significant degree of clinical angst over whether to discontinue or reduce the dose of the GDMT, which would potentially place the patient at higher risk of worsening cardiovascular function. Despite several large clinical trials showing the significant mortality and cardiovascular benefits of GDMT, rates of GDMT prescribing remain low, and rates of early GDMT discontinuation are high, with many clinicians citing concerns for EGFR decline as a large obstacle to initiation and continuation of GDMT. Designing a study to determine whether discontinuation of GDMT following EGFR decline is harmful for patients is very challenging for several reasons. First, the EGFR fluctuates frequently in HFREF both due to GDMT medications but also due to other causes. Second, with three separate classes of GDMT agents to be used in combination, there quickly become many iterations of different combinations of continuation, discontinuation, or dose change of both newly introduced (new use) GDMT as well as of previously prescribed (prevalent use) GDMT agents. The overall goal of this proposal is to use the stockholm creatinine measurement (SCREAM) cohort, a regional health utilization cohort with complete pharmacy dispensation records, to describe prescribing patterns of RAASI, MRA, and SGLT2I among patients with HF. We plan to examine EGFR changes after GDMT initiation, their association with risk of cardiovascular death and hospitalizations for HF within the context of which agent and how many combined GDMT class agents are initiated. Based on incidence of EGFR decline or not, we will then assess all the combinations of GDMT continuation, discontinuation, dose reduction or dose increase. These results will serve as preliminary data to inform design of appropriate future larger trials, including a target trial designed to emulate randomization of patients to GDMT continuation VS discontinuation following EGFR decline with the ultimate goal of increasing rates of GDMT prescribing in order to improve mortality and cardiovascular outcomes among patients with HF.

Quick answers

Who received award R03DK145928?

R03DK145928 was awarded to Tufts Medical Center Parent, Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on August 26, 2026.

How much is award R03DK145928 worth?

$133,875 has been obligated on R03DK145928.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award